Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (00656.HK, 600196.CN) has teamed up with private-equity firm TPG Capital to acquire Nasdaq-listed Chindex International Inc. for US$369 million, the Chinese drugmaker said in an emailed statement. Chindex, a New York-listed operator of hospitals in China, will be privatized and delisted after the deal. According to the statement, the buyers’ consortium, including Fosun, TPG and Chindex’s chief executive Roberta Lipson, offered US$19.50 a share for the outstanding stock, a 14 percent premium to its closing price on Feb. 14. Fosun Pharma will own 48.65 percent while TPG will hold 48.14 percent after the deal, it said.
– Contact HKEJ at [email protected]